CAR T-cell therapy for relapsed or refractory AML with NPM1 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests BSB-2002, a new type of immune cell therapy, in patients whose acute myeloid leukemia (AML) has come back or hasn't responded to prior treatments. The therapy uses the patient's own immune cells, modified in the lab to recognize and attack leukemia cells with a specific genetic mutation (NPM1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that has either returned after remission or didn't respond to at least two prior treatment regimens
- Your leukemia cells have a specific NPM1 mutation (type A, D, G, or H) confirmed by genetic testing within 3 months
- You are 18 years or older and have an HLA-A*02:01 tissue type match
- Your heart, lungs, liver, and kidneys are functioning adequately based on recent blood tests and cardiac/pulmonary assessments
- You have accessible veins for apheresis (a procedure to collect immune cells) or are willing to have a central line placed
- You are not pregnant or breastfeeding, and agree to use birth control for at least 12 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.